-
-
-
-
-
-
-
Citi raises Protagonist Therapeutics price target to $182
-
-
-
-
-
-
-
Goldman Sachs Upgrades Protagonist Therapeutics (PTGX) to Buy
-
-
-
-
-
-
-
Protagonist Therapeutics Reports Granting of Inducement Awards
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) Tops Q1 EPS by 54c
-
-
-
-
-
-
-
Protagonist presents one-year ICOTYDE psoriasis data at AAD meeting
-
-
-
-
-
-
-
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
-
-
-
-
-
-
-
JPMorgan on Protagonist Therapeutics (PTGX): 'The Kids Are Almost Out of the House'
-
479,047 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


